Cover Image
Market Research Report
Product code
1032079

Norovirus infection - Pipeline Insight, 2021

Published: Pre-Order | DelveInsight Business Research LLP | 60 Pages | Delivery time: 2-10 business days

Price

Back to Top
Norovirus infection - Pipeline Insight, 2021
Published: Pre-Order
DelveInsight Business Research LLP
Content info: 60 Pages
Delivery time: 2-10 business days
  • ALL
  • Description
  • Table of Contents
Description

DelveInsight's, "Norovirus infection - Pipeline Insight, 2021," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Norovirus infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

  • Global coverage

Norovirus infection Understanding

Norovirus infection: Overview

Norovirus infection typically causes acute gastroenteritis. It is also a common cause of food poisoning and is usually related to consumption of undercooked shellfish. People can get norovirus infection from having direct contact with an infected person, consuming contaminated food or water, or by touching contaminated surfaces. Norovirus can also cause outbreaks of acute gastroenteritis in settings where people are staying close together such as schools, elderly homes, hotels, play facilities and cruise ships. The disease affects people of all age groups and tends to be more common during winter. The virus is previously known as 'Norwalk-like viruses'.

"Norovirus infection - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Norovirus infection pipeline landscape is provided which includes the disease overview and Norovirus infection treatment guidelines. The assessment part of the report embraces, in depth Norovirus infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Norovirus infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

The companies and academics are working to assess challenges and seek opportunities that could influence Norovirus infection R&D. The therapies under development are focused on novel approaches to treat/improve Norovirus infection.

Norovirus infection Emerging Drugs Chapters

This segment of the Norovirus infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Norovirus infection Emerging Drugs

HIL-214: HilleVax

HIL-214, which is a virus-like particle (VLP) based vaccine candidate, completed a randomized, placebo-controlled Phase 2b field efficacy study in 4,712 adult subjects in which HIL-214 was well tolerated and demonstrated clinical proof of concept in preventing moderate-to-severe cases of acute gastroenteritis from norovirus infection. To date, the candidate has been studied in nine human clinical trials with safety data from over 4,500 subjects and immunogenicity data from over 2,000 subjects.

VXA G1.1 NN: Vaxart

Vaxart is developing a bivalent tablet vaccine for norovirus, a leading cause of acute viral gastroenteritis and food-borne disease in the U.S. and Europe. Vaxart has completed two Phase 1 clinical trials with its monovalent oral tablet vaccine based on the GI.1 norovirus strain, demonstrating its norovirus tablet vaccine was well tolerated and generated broad systemic and mucosal immune responses. In the recently completed clinical Phase 1b dose-optimization study in healthy adults, in which Vaxart evaluated four different dosing regimens, all vaccine recipients (100%) in the high-dose group responded as measured by a significant increase in norovirus specific B cells of both IgA and IgG subtypes. In the same group, there was at least a two-fold increase of norovirus specific antibody titers in serum in more than 90% of recipients 56 days after dosing.

Further product details are provided in the report……..

Norovirus infection: Therapeutic Assessment

This segment of the report provides insights about the different Norovirus infection drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Norovirus infection

There are approx. 8+ key companies which are developing the therapies for Norovirus infection. The companies which have their Norovirus infection drug candidates in the most advanced stage, i.e. phase II include, HilleVax.

Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like:

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Norovirus infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as:

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Norovirus infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Norovirus infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Norovirus infection drugs.

Norovirus infection Report Insights

  • Norovirus infection Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Norovirus infection Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Norovirus infection drugs?
  • How many Norovirus infection drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Norovirus infection?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Norovirus infection therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Norovirus infection and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • HilleVax
  • Vaxart
  • Cocrystal Pharma
  • Prosit Sole Biotechnology
  • Lumen Bioscience
  • Collaborations Pharmaceuticals
  • Cyanvac LLC
  • UNM Pharma Inc
  • Blue Water Vaccines

Key Products

  • HIL-214
  • VXA G1.1 NN
  • PSP 001
  • Norovirus infections antibody therapeutic
  • UMN-104
Table of Contents
Product Code: DIPI1405

Table of Contents

Introduction

Executive Summary

Norovirus infection: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Norovirus infection - DelveInsight's Analytical Perspective

Mid Stage Products (Phase II)

  • Comparative Analysis

HIL-214: HilleVax

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

VXA G1.1 NN: Vaxart

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Norovirus infection Key Companies

Norovirus infection Key Products

Norovirus infection- Unmet Needs

Norovirus infection- Market Drivers and Barriers

Norovirus infection- Future Perspectives and Conclusion

Norovirus infection Analyst Views

Norovirus infection Key Companies

Appendix

List of Tables

  • Table 1 Total Products for Norovirus infection
  • Table 2 Late Stage Products
  • Table 3 Mid Stage Products
  • Table 4 Early Stage Products
  • Table 5 Pre-clinical & Discovery Stage Products
  • Table 6 Assessment by Product Type
  • Table 7 Assessment by Stage and Product Type
  • Table 8 Assessment by Route of Administration
  • Table 9 Assessment by Stage and Route of Administration
  • Table 10 Assessment by Molecule Type
  • Table 11 Assessment by Stage and Molecule Type
  • Table 12 Inactive Products

List of Figures

  • Figure 1 Total Products for Norovirus infection
  • Figure 2 Late Stage Products
  • Figure 3 Mid Stage Products
  • Figure 4 Early Stage Products
  • Figure 5 Preclinical and Discovery Stage Products
  • Figure 6 Assessment by Product Type
  • Figure 7 Assessment by Stage and Product Type
  • Figure 8 Assessment by Route of Administration
  • Figure 9 Assessment by Stage and Route of Administration
  • Figure 10 Assessment by Molecule Type
  • Figure 11 Assessment by Stage and Molecule Type
  • Figure 12 Inactive Products